NuCana (FRA:N04) ROE % Adjusted to Book Value : -261.54% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is NuCana ROE % Adjusted to Book Value?

NuCana's ROE % for the quarter that ended in Sep. 2024 was -444.62%. NuCana's PB Ratio for the quarter that ended in Sep. 2024 was 1.70. NuCana's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -261.54%.

NuCana ROE % Adjusted to Book Value Historical Data

The historical data trend for NuCana's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuCana ROE % Adjusted to Book Value Chart

NuCana Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-12.92

-21.86

-38.12

-85.42

-153.26

NuCana Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-96.18	-245.81	-219.61	-321.43	-261.54

Competitive Comparison of NuCana's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NuCana's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NuCana's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NuCana's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NuCana's ROE % Adjusted to Book Value falls into.

NuCana ROE % Adjusted to Book Value Calculation

NuCana's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-104.22%	/	0.68
	=	-153.26%

NuCana's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-444.62%	/	1.70
	=	-261.54%

NuCana ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NuCana's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NuCana Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NuCana PLC (FRA:N04) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NCNA:USA

Address

3 Lochside Way, Edinburgh, GBR, EH12 9DT

Website

https://www.nucana.com

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

NuCana Headlines

No Headlines